BMS-986251

N/A

Report date: 2024/01/10 15:11:43
NME

Base Information

Drug NameBMS-986251
Drug Alias NameBMS-986251
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNuclear receptor ROR-gamma inverse agonists
TargetsNuclear receptor ROR-gamma
Therapy Area/IndicationsPsoriasisMetabolic Dysfunction-Associated Steatotic Liver DiseaseInflammatory Bowel Diseases +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol Myers Squibb Srlcompany
Active IndicationsN/A
Inactive IndicationsPsoriasisMetabolic Dysfunction-Associated Steatotic Liver DiseaseInflammatory Bowel Diseases +[5] 

Other Information

ATC CodeN/A
Related LinksN/A